(Q39561115)

English

Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus

scientific article published on April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Zhi-Yun Zhao

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yan-Ping Li

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yu-Ping Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Lan-Hu Hao

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Bo Fan

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yu-Huan Li

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yue-Ming Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yong-Qiang Shan

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yan-Xing Han

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yan-Ping Zhu

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jian-Rui Li

12

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Xue-Fu You

13

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Zhuo-Rong Li

14

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jian-Dong Jiang

15

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1080-1089

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

APOBEC3G inhibits elongation of HIV-1 reverse transcripts

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Small-molecule inhibition of HIV-1 Vif.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

APOBEC3G targets human T-cell leukemia virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Real-time RT-PCR for quantitation of hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

The interaction between HIV-1 Gag and APOBEC3G.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Enhancing immunity to HIV through APOBEC.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Viral hepatitis in HIV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

APOBEC-mediated viral restriction: not simply editing?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Antiviral potency of APOBEC proteins does not correlate with cytidine deamination

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

APOBEC3G & HTLV-1: inhibition without deamination

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Interferon-based therapy for chronic hepatitis C: current and future perspectives

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

High expression of APOBEC3G in patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24160

21 January 2018

Identifiers

10.1002/HEP.24160

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

release_irggwsdp6rglzedpmbvml2p25e

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39561115&oldid=2191762815"